on-invasive Screening and Detection of Cervical Cancer
Phase 2
- Conditions
- Health Condition 1: N879- Dysplasia of cervix uteri, unspecifiedHealth Condition 2: N72- Inflammatory disease of cervix uteriHealth Condition 3: N870- Mild cervical dysplasiaHealth Condition 4: N871- Moderate cervical dysplasia
- Registration Number
- CTRI/2021/02/030885
- Lead Sponsor
- Phebe George
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Patients referred for Pap smear test
2 Patients with any kind of clinically suspected lesions in the uterine cervix
Exclusion Criteria
1 Patients who had undergone previously treatments for cancer
2 Patients with transmittable diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Patient will have the possibility to get a more precise/accurate screening for cervical cancer using Cerviscan <br/ ><br>2. Location of most malignant site for biopsy using Cerviscan helps to minimize false negative and unnecessary biopsiesTimepoint: 1 week
- Secondary Outcome Measures
Name Time Method Identification of areas of tissue inflammationTimepoint: 1 week